Moderna Inc. (MRNA): Price and Financial Metrics

Moderna Inc. (MRNA): $110.59

3.18 (+2.96%)

POWR Rating

Component Grades

Momentum

C

Stability

F

Sentiment

Quality

C

Add MRNA to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#160 of 363

in industry

MRNA Price/Volume Stats

Current price $110.59 52-week high $163.24
Prev. close $107.41 52-week low $62.55
Day low $105.04 Volume 4,575,100
Day high $111.13 Avg. volume 4,421,445
50-day MA $99.03 Dividend yield N/A
200-day MA $100.48 Market Cap 42.34B

MRNA Stock Price Chart Interactive Chart >

MRNA POWR Grades

  • Value is the dimension where MRNA ranks best; there it ranks ahead of 86.42% of US stocks.
  • MRNA's strongest trending metric is Growth; it's been moving up over the last 26 weeks.
  • MRNA's current lowest rank is in the Sentiment metric (where it is better than 3.18% of US stocks).

MRNA Stock Summary

  • MODERNA INC's market capitalization of $41,399,816,286 is ahead of 93.72% of US-listed equities.
  • Of note is the ratio of MODERNA INC's sales and general administrative expense to its total operating expenses; only 9.66% of US stocks have a lower such ratio.
  • Revenue growth over the past 12 months for MODERNA INC comes in at -57.36%, a number that bests merely 4.05% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to MODERNA INC, a group of peers worth examining would be SYBX, LIFE, MGNX, SYRS, and SEEL.
  • MRNA's SEC filings can be seen here. And to visit MODERNA INC's official web site, go to www.modernatx.com.

MRNA Valuation Summary

  • MRNA's price/sales ratio is 4.2; this is 90.91% higher than that of the median Healthcare stock.
  • MRNA's EV/EBIT ratio has moved up 4.5 over the prior 62 months.

Below are key valuation metrics over time for MRNA.

Stock Date P/S P/B P/E EV/EBIT
MRNA 2023-12-29 4.2 2.8 -10.9 -15.4
MRNA 2023-12-28 4.1 2.8 -10.9 -15.3
MRNA 2023-12-27 4.2 2.9 -11.1 -15.6
MRNA 2023-12-26 4.1 2.8 -10.7 -15.0
MRNA 2023-12-22 4.0 2.7 -10.4 -14.6
MRNA 2023-12-21 3.8 2.6 -10.0 -14.0

MRNA's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • MRNA has a Quality Grade of A, ranking ahead of 98.11% of graded US stocks.
  • MRNA's asset turnover comes in at 0.829 -- ranking 29th of 682 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows MRNA's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.829 0.859 4.068
2021-06-30 0.688 0.865 4.248
2021-03-31 0.388 0.926 0.804
2020-12-31 0.183 0.990 -0.511
2020-09-30 0.084 1.000 -0.360
2020-06-30 0.048 1.000 -0.322

MRNA Price Target

For more insight on analysts targets of MRNA, see our MRNA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $286.15 Average Broker Recommendation 1.84 (Hold)

Moderna Inc. (MRNA) Company Bio


Moderna, Inc. (/məˈdɜːrnə/ mə-DUR-nə) is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA (mRNA) to produce an immune response. (Source:Wikipedia)


MRNA Latest News Stream


Event/Time News Detail
Loading, please wait...

MRNA Latest Social Stream


Loading social stream, please wait...

View Full MRNA Social Stream

Latest MRNA News From Around the Web

Below are the latest news stories about MODERNA INC that investors may wish to consider to help them evaluate MRNA as an investment opportunity.

Tech Stalls As Rising Bond Yields Spook Investors

It's been an inauspicious start to the 2024 trading year, with all three major indexes in the red midday.

TalkMarkets.com | January 2, 2024

The Biggest Losers in S&P 500 This Year: Dollar General, Moderna, and More

The five worst performers in the market benchmark so far this year could be set for brighter futures.

Yahoo | December 28, 2023

Walgreens, Nike, Moderna: Bargain hunting stocks

The most recent bull market run has been widely described as "weird," with several household stocks underperforming during the bull run on S&P 500 (^GSPC) components. Yahoo Finance Reporter Madison Mills showcases three of these companies — Moderna (MRNA), Walgreens (WBA), and Nike (NKE) — where investors may find the most value for a bargain price on the stocks. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.

Yahoo | December 28, 2023

S&P 500 Is Nearing a Record High. This Could Derail It in 2024.

Microsoft and OpenAI are sued by the New York Times for copyright infringement, Amazon plans to launch adverts on Prime Video next month, and other news to start your day.

Yahoo | December 28, 2023

The Winners and Losers: 2023 Stock Market Performance Review

The 2023 stock market saw steep declines followed by rapid upswings, but we're ending the year on a high note (even if some stocks aren't).

Jeremy Flint on InvestorPlace | December 27, 2023

Read More 'MRNA' Stories Here

MRNA Price Returns

1-mo 14.96%
3-mo 11.20%
6-mo 7.07%
1-year -25.68%
3-year -10.40%
5-year 443.44%
YTD 11.20%
2023 -44.63%
2022 -29.28%
2021 143.11%
2020 434.10%
2019 28.09%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!